O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25116286 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Wenkang Dong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Acetylglucosamine, N-Acetylglucosaminyltransferases, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Liaoning Provincial Education Department, Natural Science Foundation of Liaoning Province, Liaoning Provincial Program for the Top Discipline of Basic Medical Sciences.
Abstract (Originalsprache)
Diabetic retinopathy (DR) is a very serious diabetes complication. Changes in the O-linked N-acetylglucosamine (O-GlcNAc) modification are associated with many diseases. However, its role in DR is not fully understood. In this research, we explored the effect of O-GlcNAc modification regulation by activating AMP-activated protein kinase (AMPK) in DR, providing some evidence for clinical DR treatment in the future. Bioinformatics was used to make predictions from the database, which were validated using the serum samples of diabetic patients. As an in vivo model, diabetic mice were induced using streptozotocin (STZ) injection with/without an AMPK agonist (metformin) or an AMPK inhibitor (compound C) treatment. Electroretinogram (ERG) and H&E staining were used to evaluate the retinal functional and morphological changes. In vitro, 661 w cells were exposed to high-glucose conditions, with or without metformin treatment. Apoptosis was evaluated using TUNEL staining. The protein expression was detected using Western blot and immunofluorescence staining. The angiogenesis ability was detected using a tube formation assay. The levels of O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) in the serum changed in the DR patients in the clinic. In the diabetic mice, the ERG wave amplitude and retinal thickness decreased. In vitro, the apoptotic cell percentage and Bax expression were increased, and Bcl2 expression was decreased in the 661 w cells under high-glucose conditions. The O-GlcNAc modification was increased in DR. In addition, the expression of GFAT/TXNIP O-GlcNAc was also increased in the 661 w cells after the high-glucose treatment. Additionally, the Co-immunoprecipitation(CO-IP) results show that TXNIP interacted with the O-GlcNAc modification. However, AMPK activation ameliorated this effect. We also found that silencing the AMPKα1 subunit reversed this process. In addition, the conditioned medium of the 661 w cells may have affected the tube formation in vitro. Taken together, O-GlcNAc modification was increased in DR with photoreceptor cell degeneration and neovascularization; however, it was reversed after activating AMPK. The underlying mechanism is linked to the GFAT/TXNIP-O-GlcNAc modification signaling axis. Therefore, the AMPKα1 subunit plays a vital role in the process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
- Key Laboratory of Reproductive and Developmental Biology, Dalian Medical University, Dalian 116044, China.
- Core Laboratory of Glycobiology and Glycoengineering, College of Basic Medical Sciences, Dalian Medical University, Dalian 116044, China.
ORCID-Profile: Xiang Ren
Förderung
- Liaoning Provincial Education Department
- Natural Science Foundation of Liaoning Province
- Liaoning Provincial Program for the Top Discipline of Basic Medical Sciences
Zitieren
APA
Dong, W., Imdad, L., Xu, S., Wang, Y., Liu, C., Song, S., Li, Z., Kong, Y., Kong, L., & Ren, X. (2024). O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25116286
Vancouver
Dong W, Imdad L, Xu S, Wang Y, Liu C, Song S, et al. O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25116286
BibTeX
@article{Dong2024,
author = {Dong, Wenkang and Imdad, Laraib and Xu, Shengnan and Wang, Yinli and Liu, Chengzhi and Song, Shiyu and Li, Zechuan and Kong, Ying and Kong, Li and Ren, Xiang},
title = {O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25116286}
}
EUVIMED